Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2013 Financials
Date:11/12/2013

f BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submissions for, and FDA review of, the Company's products in development, as well as the outcomes of the Company's commercial plans) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BioDelivery Sciences to Present at the Stifel Nicolaus 2013 Healthcare Conference
2. Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
3. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
4. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
5. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
6. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
7. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
8. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
9. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
10. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
11. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... International Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased 3% ... sales decreased 4% as currency reduced sales growth by ... diluted share as reported (EPS) were $2.73, compared with ... , an increase of 9% over the prior-year ...
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes ... device company and manufacturer of the t:slim® and ... entered into non-exclusive Development Agreements with Dexcom, Inc. ... insulin pumps with the Dexcom G5 and G6 ... Tandem,s next generation pump platform with Dexcom,s future ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex ... it will report its second quarter 2015 financial results ... a conference call and live webcast at 4:30 p.m. ... clinical development programs and a general corporate update. ... the Investor Relations page of the OncoGenex website at ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... from a pivotal trial suggests that ofatumumab has activity ... , , , ... Genmab A/S (OMX: GEN) announced today positive results from ... in the treatment of refractory chronic lymphocytic leukemia (CLL). ...
... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ,Agendia, ... announced that,leading Agendia and the Netherlands Cancer Institute ... 2008 San Antonio Breast Cancer Symposium,(SABCS) and Agendia ... in Individualized Breast Cancer Therapy symposium. The San ...
Cached Medicine Technology:Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 2Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 3Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 4Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 5Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 6Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 7Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 8Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) 9Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 2Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 3Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium 4
(Date:7/31/2015)... , ... July 31, 2015 , ... ... industry players to know in predictive health analytics , Jvion continues to ... The firm creates predictive software that targets patient and population level illness to ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... important workshop at its new True North Conference Center. The medical community, social ... the Jacksonville community may be more aligned in the effort to better understand ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... According to the article published ... of the Pasadena courthouse was contained and extinguished by the city’s fire department before it ... the building at the time of the fire, and it was a fire alarm system ...
(Date:7/31/2015)... , ... July 31, 2015 , ... As part of ... community involvement and support of animal welfare organizations is essential to the longevity of ... consecutive year in the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and ... through the Girl Scout "Be a Friend First" program. Representatives from Peach State Health ... , “Peach State Health Plan and our parent company, Centene Corporation, are dedicated to ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... researchers from King's College London has revealed that more than ... to die at home, but of them are unable to ... injection of funds, end of life programmes still lack proper ... Medical Journal. ,Lead researcher Professor Irene ...
... about the goodness of Vitamin E is about to receive ... Ohio State University who studied how two forms of vitamin ... the hypothesis. ,In the past couple of decades, benefits ... Most of it in the favour while some say that ...
... molecular map and other similar discoveries that could combat ... population//. ,'The inroads can give doctors the ... Soo Khee Chee, director of the National Cancer Centre ... included experts from the University of Hong Kong, University ...
... been known for a long time that mutual antagonism between ... disease//. It has now been possible to pinpoint the exact ... hardening of coronary arteries (atherosclerosis) in women while controlling behavior ... disease in men. ,Dr. Tim Smith and fellow ...
... study done to analyze the health benefits of anti-oxidants, ... a double-edged sword//. ,Everyday, a number of ... of consuming anti-oxidants. This study has warned that under ... lead to increased risk for development of cardiovascular disease, ...
... High Court would pass judgment regarding an appeal by health ... let a 17-month-old boy die//. Lawyers who are currently handling ... quality of life is so poor and that doctors should ... of the boy and the treating physicians have not been ...
Cached Medicine News:Health News:Vitamin E: good, bad or ugly??? 2Health News:Heart disease: Men Are From Mars, Women From Venus 2Health News:Vitamin E Can Lead To Heart Disease And Cancer 2Health News:Life Or Death: Parents Await High Court Judgment 2
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
... Double lumen tubes ... ventilation., ,Each ... is packaged with ... adaptors, suction catheters ...
Used for endobronchial blockade of the left or right lung for procedures which require one-lung ventilation. Supplied sterile in peel-open packages. Intended for one-time use....
The Pedia-Trake® is designed to reduce the possibility of over penetration., ,Pedia-Trake® is used to establish an emergency airway in pediatric patients more than one year old....
Medicine Products: